Latest Regulatory News

Novonix Limited has achieved its first mass production of industrial-grade synthetic graphite and secured significant funding, advancing its position in North America's battery materials supply chain.

CurveBeam AI reports a 33% rise in device purchase orders and secures a $6.5 million placement alongside a landmark China distribution partnership. The company advances FDA regulatory milestones and establishes a vendor financing facility to boost sales.

Bioxyne Limited has reported a record quarterly revenue of A$14.1 million for Q1 FY26, driven by strong demand in Europe and Australia, alongside a strategic dual listing on the Frankfurt Stock Exchange.

CurveBeam AI has inked a decade-long exclusive partnership with a major Chinese medical device joint venture, unlocking rapid market entry and a $10 million capital boost to expand its weight bearing CT and AI solutions across Greater China.

Ampol Limited reported a robust third quarter in 2025 with refinery margins hitting a notable high, offsetting volume declines and setting the stage for strategic growth.

Star Minerals has submitted key mining and environmental permits for its Tumblegum South Gold Project, backed by exceptional shallow gold drilling results and a $1.5 million capital raise. The company targets mining commencement in early 2026 amid robust project economics.

Megado Minerals has secured all seven exploration permits for its flagship Iberian Copper Project in Northern Spain, advancing geological mapping and planning airborne geophysics and maiden drilling. The company also raised A$780,000 through an institutional placement and appointed a new independent director.

Jumbo Interactive has acquired Dream Giveaway, a leading US digital prize draw business, marking its strategic entry into the lucrative American B2C prize market. The A$55.4 million deal leverages Dream Giveaway’s established brand and loyal customer base to accelerate Jumbo’s international growth.

Challenger Limited reported a robust 9% rise in normalised net profit after tax to $456 million for FY25, alongside an 11% dividend increase, while welcoming APRA's capital reforms that promise to boost its financial resilience and growth in retirement income products.

SomnoMed reports a strong start to FY26 with 13.5% revenue growth and confirms the Clayton Sleep Institute as the first US site for its pivotal Rest Assure clinical study, backed by FDA protocol agreement.

Little Green Pharma reported a robust September quarter with revenue exceeding $10 million, driven by growth across all product lines and strong European market performance. The company is poised to benefit from upcoming regulatory reforms and operational efficiencies.

S2 Resources has agreed to sell its Fosterville exploration licence to Agnico Eagle for A$17 million and raised an additional A$3 million through a strategic share placement, positioning the company strongly for future exploration.